 |
市場調查報告書
商品編碼
2105181
尋常型天皰瘡：新型態療法、未滿足的需求與TPP洞察報告，2026年Pemphigus Vulgaris - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026 |
||||||
市場概覽
- 預計西班牙尋常型天皰瘡市場將從 2025 年的 1,200 萬美元成長到 2035 年的 2,600 萬美元。
- 推動市場成長的因素如下：
- 生物製藥和標靶免疫療法的應用日益廣泛
- 改善診斷和疾病管理
- 未來的成長取決於能夠提供更高安全性和持續緩解效果的治療方法。
尋常型天皰瘡的新療法及對TPP的深入研究
Thelansis 發布的《尋常型天皰瘡：新型療法、未滿足的需求和目標產品概況 (TPP) 洞察報告，2026》對該適應症的關鍵新興療法和主要藥物開發機會進行了全面分析，包括新興的競爭格局、未滿足的需求、目標產品概況 (TPP)、臨床試驗設計以及關鍵意見領袖 (KOL) 的見解。
尋常型天皰瘡概述
尋常型天皰瘡是一種罕見且可能危及生命的自體免疫水痘疾病。此病中，抗體攻擊連接皮膚細胞的蛋白質，導致皮膚和黏膜出現疼痛的水痘和糜爛。如不及時治療，病情會廣泛擴散。在現代治療的大部分歷史中，治療方法依賴大劑量皮質類固醇和各種免疫抑制劑的聯合應用。雖然這種方法可以控制病情，但往往會帶來嚴重的長期副作用。然而，隨著B細胞清除抗體療法成為首個獲準用於治療此疾病的生物製藥，情況發生了巨大變化。這是數十年來治療進展緩慢的一項真正突破，目前，基於臨床試驗結果顯示其療效顯著優於單用皮質類固醇，B細胞清除抗體療法已被推薦為與皮質類固醇聯合使用的一線療法。在抗體介導的自體免疫疾病中，尋常型天皰瘡的特異性在於，這種成功難以複製。由於在密切相關的疾病中取得成功的、具有全新作用機制的藥物在這裡沒有顯示出類似的效果，因此人們重新對臨床試驗結果差異的原因產生了興趣。
主要亮點
- 根據預測，德國尋常型天皰瘡（PV）患者人數將從 2025 年的 7,972 人增加到 2035 年的 11,793 人。
- 尋常型天皰瘡是一種罕見的自體免疫水痘疾病，會導致皮膚和黏膜出現疼痛性病灶。
- 儘管免疫抑制療法已經問世，但疾病復發和治療相關的副作用仍然是重大挑戰。
- 目前仍存在大量未被滿足的、能夠實現疾病持續控制的標靶治療需求。
透過對醫生和關鍵意見領袖 (KOL) 的調查所獲得的見解：
- 透過對關鍵意見領袖 (KOL) 的訪談，我們獲得了更多見解，從而進一步完善了調查結果。
- 調查問卷將根據客戶的要求進行客製化。
交付成果格式：
- PowerPoint簡報
- MS Excel
主要問題
- 詳細的競爭格局趨勢
- 管道分析
- 符合新興療法條件的患者
- 大公司
- 主要作用機制
- 發布日期預測等。
- 臨床試驗趨勢分析
- 目標患者群
- 試驗終點
- 測試設計
- 受試者招募標準等。
- 未滿足的需求和機遇
- 目前主要療法的有效性
- 未滿足需求的關鍵領域
- 主要未滿足需求的市場規模估算
- 目標產品概況
- 屬性和級別
- 醫生開立的處方
- 預期患者佔有率
- 關鍵意見領袖對領先新興療法的見解
- 意識
- 預期用途/處理線
- 以滿足重大未滿足需求的程度
- KOL評論
目標國家
- G8
- 美國
- EU5
- 法國
- 德國
- 義大利
- 西班牙
- 英國
- 日本
- 中國
大公司
- Cabaletta Bio
目錄
第1章：主要調查結果和分析師說明
- 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。
第2章 競爭情勢
- 目前的治療方法
- 重點
- 診斷和治療過程/演算法
- 主要療法概述及關鍵意見領袖見解
- 新興療法
- 重點
- 診斷和治療過程/演算法
- 領先的新興療法—概述和關鍵意見領袖見解
第3章 產品屬性分析
- 重點
- 科學屬性
- 商業性屬性
- 產品定位
第4章：初步調查
- 目前治療狀態
- 主要治療方法與目標患者族群的比較
- 主要特點和優勢
- 未來治療環境
- 當前挑戰
- 未滿足的需求
- 新興療法
- 主要治療方法與目標患者族群的比較
- 主要特點和優勢
- 未來治療前景
- 未滿足的需求和關鍵意見領袖的期望
第5章：未滿足的需求和TPP分析
- 新興療法的主要未滿足需求和未來成就
- TPP分析與KOL預期
第6章 監理與報銷環境
第7章附錄
Pemphigus Vulgaris Emerging Therapy and TPP Insights
Thelansis's "Pemphigus Vulgaris Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
Pemphigus Vulgaris Overview
Pemphigus vulgaris is a rare, potentially life-threatening autoimmune blistering disease in which antibodies attack proteins responsible for holding skin cells together, causing painful blistering and erosion across the skin and mucous membranes that can become extensive without treatment. For most of the modern treatment era, care relied on high-dose corticosteroids paired with various immunosuppressants, an approach that could control the disease but often at the cost of significant long-term side effects. That changed when a B-cell depleting antibody therapy became the first biologic approved for the condition, a genuine milestone after decades without a major treatment advance, and it is now recommended alongside corticosteroids as first-line therapy based on trial evidence showing meaningfully better outcomes than steroids alone. What makes pemphigus somewhat unusual within antibody-mediated autoimmune disease is that this success has been difficult to replicate, with newer mechanisms that succeeded in closely related conditions failing to show similar benefit here, prompting renewed interest in why trial outcomes diverge.
Key Highlights
- In Germany, prevalent Pemphigus Vulgaris (PV) cases are projected to increase from 7,972 in 2025 to 11,793 by 2035.
- Pemphigus Vulgaris is a rare autoimmune blistering disease causing painful skin and mucosal lesions.
- Despite available immunosuppressive therapies, disease relapse and treatment-related adverse effects remain major challenges.
- Significant unmet need remains for targeted therapies that provide durable disease control.
Market Overview
- The Spain Pemphigus Vulgaris market is projected to grow from $12M in 2025 to $26M by 2035.
- Market growth is driven by:
- Increasing adoption of biologic and targeted immunotherapies
- Improved diagnosis and disease management
- Future growth will depend on therapies offering sustained remission with improved safety profiles.
Insights driven by surveys with physician / key opinion leaders:
- Survey findings are corroborated and enriched by insights from interviews with leading KOLs
- Survey is customized based on client requirements
Deliverables format:
- PowerPoint presentation
- MS Excel
Key business questions answered:
- Detailed emerging competitive landscape
- Pipeline analysis
- Target patients for emerging therapies
- Key companies
- Key mechanism of actions
- Launch date estimates, etc.
- Clinical trial landscape analysis
- Target patient segments
- Trial endpoints
- Trial design
- Recruitment criteria, etc.
- Unmet Needs and Opportunities
- Performance of key current therapies
- Top areas of unmet needs
- Opportunity sizing for key unmet needs
- Target Product Profiles
- Attributes and levels
- Physician likelihood of prescribing
- Expected patient shares
- KOL insights on key emerging therapies
- Level of awareness
- Expected use / line of therapy
- Extent to fulfil key unmet needs
- KOL quotes
Countries Covered
- G8
- United States
- EU5
- France
- Germany
- Italy
- Spain
- U.K.
- Japan
- China
Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country
Companies Mentioned
- Cabaletta Bio
Table of Contents
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.
2. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies - profiles and KOL insights
- Emerging therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key emerging therapies - profiles and KOL insights
3. Product Attribute Analysis
- Key takeaways
- Scientific attributes
- Commercial attributes
- Product positioning
4. Primary Market Research
- Current treatment landscape
- Key therapies vs. focused patient segment
- Key attributes and benefits
- Futures treatment landscape
- Current challenges
- Unmet needs
- Emerging therapies
- Key therapies vs. focused patient segment
- Key attributes and benefits
- Futures treatment landscape
- Unmet needs and KOL expectations
5. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
